| 18.72 0 (0%) | 09-30 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Hanger, Inc. is a long-established American enterprise specializing in the provision of orthotic and prosthetic (O&P) services throughout the United States. Its business operations are segmented into two primary areas: Patient Care and Products & Services. The Patient Care division encompasses the Hanger Clinic network, which it owns and manages. These clinics excel in the custom design, fabrication, and delivery of O&P devices, serving patients directly through their extensive network of clinics and smaller satellite locations. This segment also offers vital payor network contracting services to other O&P providers. The Products & Services segment is multifaceted, focusing on the distribution of a wide array of O&P components, parts, and complete devices to independent O&P practitioners. It is also involved in the research and development of advanced rehabilitation technologies and delivers evidence-based clinical programs for post-acute rehabilitation to patients across approximately 4,000 skilled nursing and other post-acute care facilities. Additionally, this segment manufactures and sells specialized therapeutic footwear for diabetic patients within the podiatric market. As of December 31, 2021, Hanger maintained a substantial presence with approximately 760 patient care clinics and 115 satellite sites, spanning 47 states and the District of Columbia. Beyond direct patient care, the company actively distributes O&P devices and components, manages O&P networks, and provides comprehensive therapeutic solutions to both patients and businesses in acute, post-acute, and clinic environments. Originally established in Austin, Texas, in 1861, the firm was formerly known as Hanger Orthopedic Group, Inc., before officially adopting the name Hanger, Inc. in June 2012.
Fri, 14 Oct 2022
Peter A Stoy Net Worth (2026) - GuruFocus
Mon, 03 Oct 2022
Hanger Completes Acquisition by Patient Square Capital - citybiz
Fri, 22 Jul 2022
Latham Advises Patient Square Capital on the Key Healthcare Regulatory Antitrust and Government - Latham & Watkins LLP
Thu, 10 Feb 2022
Forbes Names Hanger One of America’s Best Employers for Second Consecutive Year - Business Wire
Thu, 24 Sep 2020
Hanger Announces Appointment of Dr. Mark M. Jones to Board of Directors - Business Wire
Tue, 01 Mar 2016
Scandal Knocks Prosthetics Firm Off Stock Exchange - Medical Device and Diagnostic industry
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|